You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas
SBC: NEONC TECHNOLOGIES INC Topic: 102Despite important advances in surgical techniques, imagistic modalities and computer-assisted stereotactic delivery of radiation therapy, the prognosis for patients with glioblastoma (GB) remains grim and has not significantly changed in decades. The Stupp protocol—i.e., concurrent temozolomide (TMZ) plus conformal external beam radiotherapy (EBRT) followed by adjuvant TMZ—remains the cornerst ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Integrated Platform for Mass-Spectrometric Studies of Protein Structure
SBC: PROTEIN METRICS INC Topic: 400Summary Technology for studying the higher order structure (HOS) and interactions of biomolecules is a highlighted NIGMS SBIR/STTR research topic. Mass-spectrometric methods for studying HOS include hydroxyl radical footprinting as well as chemical methods to covalently label amino acid side-chain functional groups, and also hydrogen/deuterium exchange (HDX) on protein backbone amides. These metho ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.
SBC: REKOVAR INC Topic: NIDAPROJECT SUMMARY Neonatal abstinence syndrome (NAS) is an opioid withdrawal syndrome that develops shortly after birth to in utero-exposed neonates. The cost of NAS is high: newborns with NAS are typically receive care in the Neonatal Intensive Care Unit (NICU), where the daily cost of care is high. Nearly 22,000 infants are born with NAS each year at a cost of $1.5 billion1. Moreover, medication-b ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents
SBC: Grannus Therapeutics, Inc. Topic: NCIAbstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Develop and Commercialize the Bayesian Dose-Response Modeling System and Services
SBC: KS & ASSOCIATES LLC Topic: NIEHSPROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease
SBC: NEURODON, LLC Topic: NIANeurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy
SBC: SIGNAL SOLUTIONS, LLC Topic: 100EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy There is an urgent need for research into treatment options for epilepsy and other seizure disorders. Animal models are increasingly used to understand disease mechanisms and to screen promising therapeutic approaches. Animal epilepsy model use typically requires expensive and labor-intensive experimentation, with invasive EE ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
SBC: Medosome Biotec, LLC Topic: NICHDProject Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Sorting live cells using RNA-targeting CRISPR-Cas9 (RCas9)
SBC: DAHLIA BIOSCIENCES, INC. Topic: 172Project Summary/Abstract Transcriptomic-based approaches, and in recent years, single-cell RNA sequencing, are revolutionizing our understanding of cellular heterogeneity, opening up a new route to identify novel cell markers at unprecedented scale across many different cell types. RNA-based live-cell sorting opens up andgt;99% of the marker space to enable higher specificity cell sorting. Howe ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...
STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense